cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment.
AffiliationOncology Research Laboratory, Derby City Hospital, UK.
MetadataShow full item record
AbstractA study on the in vitro sensitivity of tumour cells from patients with ovarian cancer has been carried out in parallel with a clinical study designed to evaluate the role of high-dose cis-platinum (CIS) as first-line chemotherapy. A total of 50 samples from 102 patients have been successfully cultured and screened for in vitro chemosensitivity to 7 drugs, including CIS. The malignant nature of cells growing in culture was confirmed using a combination of karyology, morphology and immunohistochemical staining with HMFG2. Tumours were graded as sensitive (less than 40% of control 3H-leucine incorporation), intermediate (41-60% of control) or resistant (greater than 61% of control) to CIS. Correlation of in vitro sensitivity to cis-platinum with clinical response to cis-platinum assessed using CT scan and second-look laparotomy, showed positive correlation in 9/11 (89%) patients (8 = S/S; 1 = R/R); positive correlation between in vitro sensitivity to phosphoramide mustard and clinical response was also found in 4/6 patients receiving cyclophosphamide (3 = S/S; 1 = R/R). All patients with sensitive tumours showed a clinical response to cis-platinum. Comparison of cis-platinum sensitivity with sensitivity to phosphoramide mustard and melphalan showed that some tumours were sensitive only to cis-platinum; resistance to cis-platinum and sensitivity to phosphoramide mustard/melphalan was an infrequent occurrence. Some tumours which were resistant to cis-platinum showed sensitivity to adriamycin and bleomycin, particularly those from untreated patients. Sensitivity to 5-fluorouracil and resistance to cis-platinum was found in approximately equal proportions of tumours in both the treated and untreated groups.
Citationcis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. 1987, 56 (6):763-73 Br. J. Cancer
JournalBritish Journal of Cancer
- Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay.
- Authors: Simmonds AP, McDonald EC
- Issue date: 1984 Sep
- In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
- Authors: Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, Salmon SE
- Issue date: 1994 Dec
- Medical therapy of advanced malignant epithelial tumours of the ovary.
- Authors: Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A
- Issue date: 2000 Oct-Dec
- Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
- Authors: Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP
- Issue date: 2002 Oct
- The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
- Authors: Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ
- Issue date: 2004 Jul